Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Sacco, Rodolfo; Messina, Vito; Gentilucci, Umberto Vespasiani; Adinolfi, Luigi Elio; Ascione, Antonio; Barbarini, Giorgio; Barlattani, A.; Castaldo, Giuseppe; Cozzolongo, Raffaele; Fimiani, Basilio; Francavilla, Ruggiero; Furlan, Caterina; Garrucciu, Giovanni; Iovinella, Vincenzo; Rinaldi, Luca; Marignani, Massimo; Begini, Paola; Palitti, Valeria Pace; Pellicelli, A.; Scifo, G.; Facciorusso, Antonio; Giacomelli, Luca; Shah, Aashni; Bertino, Gaetano; Perazzo, Serena; Bresci, G.; Izzi, Antonio

doi:10.7573/dic.2020-4-11

Cited by 2 publications

(1 citation statement)

References 26 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The DAAs directly target specific steps within the HCV replication cycle. Clinical evidence robustly supports the efficacy of DAA regimens, with data indicating that over 95% of patients treated with DAAs achieve an SVR, which is clinically equated with virological cure [ 325 , 326 , 327 , 328 , 329 , 330 ]. A summary of four common, currently approved DAA regimens is presented in ( Table 2 ).…”

Section: Treatment Of Hcvmentioning

confidence: 99%

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Sallam,

Khalil

2024

Microorganisms

View full text Add to dashboard Cite

Hepatitis C virus (HCV) remains a significant global health challenge. Approximately 50 million people were living with chronic hepatitis C based on the World Health Organization as of 2024, contributing extensively to global morbidity and mortality. The advent and approval of several direct-acting antiviral (DAA) regimens significantly improved HCV treatment, offering potentially high rates of cure for chronic hepatitis C. However, the promising aim of eventual HCV eradication remains challenging. Key challenges include the variability in DAA access across different regions, slightly variable response rates to DAAs across diverse patient populations and HCV genotypes/subtypes, and the emergence of resistance-associated substitutions (RASs), potentially conferring resistance to DAAs. Therefore, periodic reassessment of current HCV knowledge is needed. An up-to-date review on HCV is also necessitated based on the observed shifts in HCV epidemiological trends, continuous development and approval of therapeutic strategies, and changes in public health policies. Thus, the current comprehensive review aimed to integrate the latest knowledge on the epidemiology, pathophysiology, diagnostic approaches, treatment options and preventive strategies for HCV, with a particular focus on the current challenges associated with RASs and ongoing efforts in vaccine development. This review sought to provide healthcare professionals, researchers, and policymakers with the necessary insights to address the HCV burden more effectively. We aimed to highlight the progress made in managing and preventing HCV infection and to highlight the persistent barriers challenging the prevention of HCV infection. The overarching goal was to align with global health objectives towards reducing the burden of chronic hepatitis, aiming for its eventual elimination as a public health threat by 2030.

show abstract

Section: Treatment Of Hcvmentioning

confidence: 99%

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Sallam,

Khalil

2024

Microorganisms

View full text Add to dashboard Cite

show abstract

Hepatitis C Virus: History and Current Knowledge

Topi,

Gaxhja,

Charitos

et al. 2024

Gastroenterology Insights

View full text Add to dashboard Cite

According to the World Health Organization (WHO), the incidence of HCV remains high (around 1.5 million new patients every year), and 80% of patients with acute infection will progress to chronic hepatitis and develop cirrhosis and even liver cancer. Furthermore, some extrahepatic pathologies may be correlated with HCV (such as mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, glomerulonephritis, Sjogren’s syndrome, Hodgkin and non-Hodgkin cell lymphoma, and others). In view of these secondary complications, together with the substantial risk of liver damage, the objective of this review was to research and suggest, based on the scientific evidence, the appropriate clinical use of drugs with direct antiviral action (AAD) according to the criteria of international medical organizations. This is to maximize the clinical benefits for patients and to facilitate access to DAA therapy for all patients with chronic hepatitis C. According to the WHO, no vaccine is currently available, and therapies using new antivirals and their combinations are now an effective and safer solution for patients than they have been in the past with the use of interferons. This study aims to analyse the history and knowledge of the pathogenic biomolecular mechanisms and current therapies for HCV.

show abstract

Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study

Cited by 2 publications

References 26 publications

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Contemporary Insights into Hepatitis C Virus: A Comprehensive Review

Hepatitis C Virus: History and Current Knowledge

Contact Info

Product

Resources

About